Novel Diabetes Therapies in CVD Risk Reduction

The available novel diabetes therapies and their impact on cardiovascular and cardiometabolic risk reduction are discussed by guests Chris Memering, MSN, RN, CDCES, BC-ADM, FADCES, and Sun Kim, MD. A particular emphasis on GLP-1 receptor agonists, and the patients for whom they are guideline recommended, as well as ongoing research are also covered.

CE LINK: pcna.net/podcast/novel-diabetes-therapies-in-cvd-risk-reduction

GLP-1 RAs: An updated reivew of head-to-head clinical studies: https://pubmed.ncbi.nlm.nih.gov/33767808/ 

GLP1-RAs: CV benefts & mechanisms of action (Ussher & Drucker): https://pubmed.ncbi.nlm.nih.gov/36977782/ 

GLP-1 & Underlying Beneficial Actions in Alzheimer's disease, Hypertension, & NASH: ttps://pubmed.ncbi.nlm.nih.gov/34552561/

Incretins & microvascular complications of diabetes: https://pubmed.ncbi.nlm.nih.gov/37597048/ 

Management of Type 2 Diabetes 2022. A Consensus Report by ADA, EASD. doi: 10.2337/dci22-0034.

ADA Standards of Care in Diabetes 2023. https://diabetesjournals.org/care/issue/46/Supplement_1

AACE Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm--2023 Update. 

https://www.endocrinepractice.org/article/S1530-891X(23)00034-4/fulltext

Cardio-renal-metabolic connection: a review of the Evidence. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391899/pdf/12933_2023_Article_1937.pdf 

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.